Skip to main content
Erschienen in:

05.10.2019 | Melasma | derma aktuell

Von Hydrochinon bis PRP

Neue Therapien der Hyperpigmentierung am Horizont?

verfasst von: Dr. Miriam Sonnet

Erschienen in: ästhetische dermatologie & kosmetologie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Goldstandard für die Behandlung von Pigmentunregelmäßigkeiten der Haut ist nach wie vor Hydrochinon. Aber auch andere Therapien, wie plättchenreiches Plasma, sind in Sicht — deren Wirksamkeit muss sich allerdings in weiteren Studien zeigen.
Literatur
2.
Zurück zum Zitat Brenner M, Berking C. Grundlagen der Hautpigmentierung. Der Hautarzt. 2010; 61: 554–60CrossRef Brenner M, Berking C. Grundlagen der Hautpigmentierung. Der Hautarzt. 2010; 61: 554–60CrossRef
3.
Zurück zum Zitat Bayerl C. Behandlung von Hyperpigmentierungen. ästhetische dermatologie & kosmetologie. 2015; 7: 30–35CrossRef Bayerl C. Behandlung von Hyperpigmentierungen. ästhetische dermatologie & kosmetologie. 2015; 7: 30–35CrossRef
5.
Zurück zum Zitat Filoni A et al. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol. 2019; 18: 458–63CrossRef Filoni A et al. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol. 2019; 18: 458–63CrossRef
6.
Zurück zum Zitat Kwon SH. Melasma: Updates and perspectives. Exp Dermatol. 2019; 28: 704–8CrossRef Kwon SH. Melasma: Updates and perspectives. Exp Dermatol. 2019; 28: 704–8CrossRef
7.
Zurück zum Zitat Giménez García RM, Carrasco Molina S. Drug-Induced Hyperpigmentation: Review and Case Series. J Am Board Fam Med. 2019; 32: 628–38CrossRef Giménez García RM, Carrasco Molina S. Drug-Induced Hyperpigmentation: Review and Case Series. J Am Board Fam Med. 2019; 32: 628–38CrossRef
8.
Zurück zum Zitat Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010; 3: 20–31PubMedPubMedCentral Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010; 3: 20–31PubMedPubMedCentral
9.
Zurück zum Zitat Roberts WE. Pollution as a risk factor for the development of melasma and other skin disorders of facial hyperpigmentation is there a case to be made? J Drugs Dermatol. 2015; 14: 337–41PubMed Roberts WE. Pollution as a risk factor for the development of melasma and other skin disorders of facial hyperpigmentation is there a case to be made? J Drugs Dermatol. 2015; 14: 337–41PubMed
10.
Zurück zum Zitat Vierkötter A et al. Airborne particle exposure and extrinsic skin aging. J Invest Dermatol. 2010; 130: 2719–26CrossRef Vierkötter A et al. Airborne particle exposure and extrinsic skin aging. J Invest Dermatol. 2010; 130: 2719–26CrossRef
11.
Zurück zum Zitat Ferreira Cestari T et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007; 6: 36–9CrossRef Ferreira Cestari T et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007; 6: 36–9CrossRef
12.
Zurück zum Zitat Ahmad Nasrollahi S, Sabet Nematzadeh M, Samadi A, Ayatollahi A, Yadangi S, Abels C et al. Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin. Clin Cosmet Investig Dermatol. 2019; 12: 437–44CrossRef Ahmad Nasrollahi S, Sabet Nematzadeh M, Samadi A, Ayatollahi A, Yadangi S, Abels C et al. Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin. Clin Cosmet Investig Dermatol. 2019; 12: 437–44CrossRef
13.
Zurück zum Zitat Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004; 74: 319–22PubMed Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004; 74: 319–22PubMed
14.
Zurück zum Zitat Monteiro RC et al. A Comparative Study of the Efficacy of 4% Hydroquinone vs 0.75% Kojic Acid Cream in the Treatment of Facial Melasma. Indian J Dermatol. 2013; 58: 157CrossRef Monteiro RC et al. A Comparative Study of the Efficacy of 4% Hydroquinone vs 0.75% Kojic Acid Cream in the Treatment of Facial Melasma. Indian J Dermatol. 2013; 58: 157CrossRef
15.
Zurück zum Zitat Deo KS et al. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013; 58: 281–5CrossRef Deo KS et al. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013; 58: 281–5CrossRef
16.
Zurück zum Zitat Mazurek K, Pierzchała E. Comparison of efficacy of products containing azelaic acid in melasma treatment. J Cosmet Dermatol. 2016; 15: 269–82CrossRef Mazurek K, Pierzchała E. Comparison of efficacy of products containing azelaic acid in melasma treatment. J Cosmet Dermatol. 2016; 15: 269–82CrossRef
17.
Zurück zum Zitat Dayal S et al. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. J Cosmet Dermatol. 2017; 16: 35–42CrossRef Dayal S et al. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. J Cosmet Dermatol. 2017; 16: 35–42CrossRef
18.
Zurück zum Zitat Kirsch B et al. Evaluating the Efficacy, Safety, and Tolerability of the Combination of Tazarotene, Azelaic Acid, Tacrolimus, and Zinc Oxide for the Treatment of Melasma: A Pilot Study. J Clin Aesthet Dermatol. 2019; 12: 40–5PubMedPubMedCentral Kirsch B et al. Evaluating the Efficacy, Safety, and Tolerability of the Combination of Tazarotene, Azelaic Acid, Tacrolimus, and Zinc Oxide for the Treatment of Melasma: A Pilot Study. J Clin Aesthet Dermatol. 2019; 12: 40–5PubMedPubMedCentral
20.
Zurück zum Zitat Hollinger JC et al. Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review. J Clin Aesthet Dermatol. 2018; 11: 28–37PubMedPubMedCentral Hollinger JC et al. Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review. J Clin Aesthet Dermatol. 2018; 11: 28–37PubMedPubMedCentral
21.
Zurück zum Zitat Ertam I et al. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008; 35: 570–4CrossRef Ertam I et al. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008; 35: 570–4CrossRef
22.
Zurück zum Zitat Makino ET et al. Evaluation of a hydroquinone-free skin brightening product using in-vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. J Drugs Dermatol. 2013; 12: s16–s20PubMed Makino ET et al. Evaluation of a hydroquinone-free skin brightening product using in-vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. J Drugs Dermatol. 2013; 12: s16–s20PubMed
23.
Zurück zum Zitat Griffiths CE et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993; 129: 415–21CrossRef Griffiths CE et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993; 129: 415–21CrossRef
24.
Zurück zum Zitat Hegyi V, Hegyi J. Methoden und Mittel zur Pigmentierung und Depigmentierung. Der Hautarzt. 2010; 61: 586–92CrossRef Hegyi V, Hegyi J. Methoden und Mittel zur Pigmentierung und Depigmentierung. Der Hautarzt. 2010; 61: 586–92CrossRef
25.
Zurück zum Zitat Rivas S, Pandya AG. Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review. Am J Clin Dermatol. 2013; 14: 359–76CrossRef Rivas S, Pandya AG. Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review. Am J Clin Dermatol. 2013; 14: 359–76CrossRef
27.
Zurück zum Zitat Choi S et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002; 27: 513–5CrossRef Choi S et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002; 27: 513–5CrossRef
28.
Zurück zum Zitat Zubair S, Mujtaba G. Comparison of efficacy of topical 2% liquiritin, topical 4% liquiritin and topical 4% hydroquinone in the management of melasma. Journal of Pakistan Association of Dermatologists. 2009; 19: 158–63 Zubair S, Mujtaba G. Comparison of efficacy of topical 2% liquiritin, topical 4% liquiritin and topical 4% hydroquinone in the management of melasma. Journal of Pakistan Association of Dermatologists. 2009; 19: 158–63
29.
Zurück zum Zitat Draelos ZD. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone. J Am Acad Dermatol. 2015; 72: 105–7CrossRef Draelos ZD. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone. J Am Acad Dermatol. 2015; 72: 105–7CrossRef
30.
Zurück zum Zitat Alvin G et al. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: a randomized, single-blind, placebo-controlled trial. J Drugs Dermatol. 2011; 10: 1025–31PubMed Alvin G et al. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: a randomized, single-blind, placebo-controlled trial. J Drugs Dermatol. 2011; 10: 1025–31PubMed
31.
Zurück zum Zitat Castanedo-Cazares JP et al. Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol. 2013; 6: 29–36CrossRef Castanedo-Cazares JP et al. Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol. 2013; 6: 29–36CrossRef
32.
Zurück zum Zitat Janney MS et al. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg. 2019; 12: 63–7PubMedPubMedCentral Janney MS et al. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg. 2019; 12: 63–7PubMedPubMedCentral
33.
Zurück zum Zitat Zhu CY et al. Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol. 2019; 29: 55–8PubMed Zhu CY et al. Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol. 2019; 29: 55–8PubMed
35.
Zurück zum Zitat Padhi T, Pradhan S. Oral Tranexamic Acid with Fluocinolone-Based Triple Combination Cream Versus Fluocinolone-Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial. Indian J Dermatol. 2015; 60: 520PubMedPubMedCentral Padhi T, Pradhan S. Oral Tranexamic Acid with Fluocinolone-Based Triple Combination Cream Versus Fluocinolone-Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial. Indian J Dermatol. 2015; 60: 520PubMedPubMedCentral
36.
Zurück zum Zitat Wattanakrai P et al. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010; 36: 76–87CrossRef Wattanakrai P et al. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010; 36: 76–87CrossRef
37.
Zurück zum Zitat Imhof L et al. A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg. 2016; 42: 853–7CrossRef Imhof L et al. A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg. 2016; 42: 853–7CrossRef
38.
Zurück zum Zitat Abdel-Raouf Mohamed H et al. Comparative study of fractional Erbium: YAG laser vs combined therapy with topical steroid as an adjuvant treatment in melasma. J Cosmet Dermatol. 2019; 18: 517–23CrossRef Abdel-Raouf Mohamed H et al. Comparative study of fractional Erbium: YAG laser vs combined therapy with topical steroid as an adjuvant treatment in melasma. J Cosmet Dermatol. 2019; 18: 517–23CrossRef
39.
Zurück zum Zitat Merchán WH et al. Platelet-rich plasma, a powerful tool in dermatology. J Tissue Eng Regen Med. 2019; 13: 892–901CrossRef Merchán WH et al. Platelet-rich plasma, a powerful tool in dermatology. J Tissue Eng Regen Med. 2019; 13: 892–901CrossRef
40.
Zurück zum Zitat Hofny ERM et al. Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatolog Treat. 2019; 30: 396–401CrossRef Hofny ERM et al. Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatolog Treat. 2019; 30: 396–401CrossRef
41.
Zurück zum Zitat Cayırlı M et al. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol. 2014; 26: 401–2CrossRef Cayırlı M et al. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol. 2014; 26: 401–2CrossRef
43.
Zurück zum Zitat Arrowitz C et al. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol. 2019; 139: 1691–1698.e6CrossRef Arrowitz C et al. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol. 2019; 139: 1691–1698.e6CrossRef
44.
Zurück zum Zitat Sarkar R et al. Role of broad-spectrum sunscreen alone in the improvement of melasma area severity index (MASI) and Melasma Quality of Life Index in melasma. J Cosmet Dermatol. 2019; 18: 1066–73PubMed Sarkar R et al. Role of broad-spectrum sunscreen alone in the improvement of melasma area severity index (MASI) and Melasma Quality of Life Index in melasma. J Cosmet Dermatol. 2019; 18: 1066–73PubMed
45.
Zurück zum Zitat Grimes PE et al. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2018; 5: 30–6CrossRef Grimes PE et al. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2018; 5: 30–6CrossRef
46.
Zurück zum Zitat Jacobus Berlitz S et al. Azelaic acid-loaded nanoemulsion with hyaluronic acid - a new strategy to treat hyperpigmentary skin disorders. Drug Dev Ind Pharm. 2019; 45: 642–50CrossRef Jacobus Berlitz S et al. Azelaic acid-loaded nanoemulsion with hyaluronic acid - a new strategy to treat hyperpigmentary skin disorders. Drug Dev Ind Pharm. 2019; 45: 642–50CrossRef
47.
Zurück zum Zitat Phacharapiyangkul N et al. Effect of Sucrier Banana Peel Extracts on Inhibition of Melanogenesis through the ERK Signaling Pathway. Int J Med Sci. 2019; 16: 602–6CrossRef Phacharapiyangkul N et al. Effect of Sucrier Banana Peel Extracts on Inhibition of Melanogenesis through the ERK Signaling Pathway. Int J Med Sci. 2019; 16: 602–6CrossRef
48.
Zurück zum Zitat Mansouri P et al. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015; 173: 209–17CrossRef Mansouri P et al. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015; 173: 209–17CrossRef
49.
Zurück zum Zitat Adalatkhah H, Sadeghi-Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. Drug Des Devel Ther. 2015; 9: 4219–25PubMedPubMedCentral Adalatkhah H, Sadeghi-Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. Drug Des Devel Ther. 2015; 9: 4219–25PubMedPubMedCentral
52.
Zurück zum Zitat Ryu JH et al. A study of the human skin-whitening effects of resveratryl triacetate. Arch Dermatol Res. 2015; 307: 239–47CrossRef Ryu JH et al. A study of the human skin-whitening effects of resveratryl triacetate. Arch Dermatol Res. 2015; 307: 239–47CrossRef
Metadaten
Titel
Von Hydrochinon bis PRP
Neue Therapien der Hyperpigmentierung am Horizont?
verfasst von
Dr. Miriam Sonnet
Publikationsdatum
05.10.2019
Verlag
Springer Medizin
Erschienen in
ästhetische dermatologie & kosmetologie / Ausgabe 5/2019
Print ISSN: 1867-481X
Elektronische ISSN: 2198-6517
DOI
https://doi.org/10.1007/s12634-019-0092-x

Weitere Artikel der Ausgabe 5/2019

ästhetische dermatologie & kosmetologie 5/2019 Zur Ausgabe

Passend zum Thema

Allergen unter der Haut: Wenn Tattoos plötzlich Ärger machen

Tätowierungen können nicht nur künstlerisch, sondern auch gesundheitlich komplex sein. Manche Pigmente bergen Gefahren, die sich oft erst Jahre später zeigen. Was steckt hinter den verzögerten Reaktionen, und wie kann man sie behandeln?

ANZEIGE

Erhöhte Aufnahme von Tattoofarbe mit Dexpanthenol

PD Dr. Matthias Bartneck, forschender Biologe an der RWTH Aachen, stellte eine aktuelle in-vitro Studie vor, bei welcher unter anderem der Einfluss von Dexpanthenol auf die Aufnahme von Tattoo-Farbe sowie die Beständigkeit der Farben unter der Haut untersucht wurden. Andy Engel, Tätowierer, berichtete von seinen Erfahrungen aus dem Tattoo-Studio.

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

  • Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Bayer Vital GmbH